Blockade of ERK signaling by BRAF inhibitor inactivates ERK-dependent feedback, and then reactivates multiple RTKs and their downstream ERK and AKT signaling cascades, thereby causing the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitor. Here, AKT1 is linked to thyroid gland carcinoma.